Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL CITRATE versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL CITRATE versus QOLIANA.
FENTANYL CITRATE vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist that primarily acts on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and euphoria. It also interacts with kappa and delta opioid receptors to a lesser extent. By binding to these receptors, fentanyl inhibits adenylate cyclase, reduces cAMP production, closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels, resulting in hyperpolarization and reduced neurotransmitter release.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
Initial adult dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; for anesthesia induction 2-20 mcg/kg IV.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 3-12 hours (mean 4-6 hours in adults). Context: Prolonged with hepatic impairment, elderly, or continuous infusion (context-sensitive half-life increases with infusion duration).
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Primarily hepatic metabolism (N-dealkylation to norfentanyl and other metabolites); less than 10% excreted unchanged in urine; approximately 9% excreted in feces via biliary elimination.
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist